Company Description
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia.
It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.
The company’s drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection.
It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines.
It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs.
TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 25, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Harlan Weisman |
Contact Details
Address: 1751 River Run, Suite 400 Fort Worth, Texas 76107 United States | |
| Phone | 817 438 6168 |
| Website | tffpharma.com |
Stock Details
| Ticker Symbol | TFFP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001733413 |
| CUSIP Number | 87241J104 |
| ISIN Number | US87241J2033 |
| Employer ID | 82-4344737 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Harlan F. Weisman | President, Chief Executive Officer and Director |
| Kirk Allen Coleman | Chief Financial Officer, Treasurer and Secretary |
| Dr. Zamaneh Mikhak M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | 10-Q | Quarterly Report |
| Nov 19, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 14, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 10-Q | Quarterly Report |
| Aug 6, 2024 | 8-K | Current Report |
| Jul 1, 2024 | 8-K | Current Report |
| Jun 14, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |